Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4395089 · 2 trials · 2 indications
The percentage of participants who achieve endoscopic response at week 12 of Study Period 1.
| Arm | Type | Description |
|---|---|---|
| Mirikizumab | ACTIVE_COMPARATOR | Study Period 1: Mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC. |
| LY4395089 and Mirikizumab Co-Administration | EXPERIMENTAL | Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC. |
| LY4395089 | EXPERIMENTAL | LY4395089 administered orally |
| Itraconazole | EXPERIMENTAL | Itraconazole administered orally |
| LY4395089 + Itraconazole | EXPERIMENTAL | LY4395089 and Itraconazole administered orally |
| Name | Type | Description |
|---|---|---|
| LY4395089 | DRUG | Administered orally |
| Mirikizumab - Intravenous (IV) | DRUG | Administered IV |
| Mirikizumab - Subcutaneous (SC) | DRUG | Administered SC |
| Itraconazole | DRUG | Administered orally |
Inclusion Criteria: Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below: * Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
LY4395089 is an investigational small molecule being studied for Crohn's disease. It is currently in Phase 2 clinical development, evaluated in combination with mirikizumab (LY3074828) compared to mirikizumab alone in adults with Crohn's disease. The drug is not approved and remains under investigation.
The molecular target of LY4395089 has not been disclosed in available clinical trial information. The drug is a small molecule being developed by Eli Lilly and Company for gastrointestinal conditions, specifically Crohn's disease. Its mechanism of action is not publicly detailed in the current trial data.
LY4395089 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The company is conducting clinical trials of LY4395089 for Crohn's disease and in healthy participants.
LY4395089 is in Phase 2 clinical development for Crohn's disease. A Phase 1 study in healthy participants has been completed. The drug is investigational and has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical trials.
LY4395089 is being studied in two clinical trials. NCT07483099 is a Phase 2 study in adults with Crohn's disease, comparing LY4395089 plus mirikizumab to mirikizumab alone, currently recruiting in multiple countries. NCT07592572 is a completed Phase 1 study of itraconazole's effects on LY4395089 in healthy participants.
No, LY4395089 is not the same as mirikizumab. Mirikizumab, also known as LY3074828, is a separate drug developed by Eli Lilly. In a Phase 2 trial, LY4395089 is being tested in combination with mirikizumab, and the study compares this combination to mirikizumab alone in Crohn's disease.